FMT – Fecal Microbiota Transplantation Explained
FMT (Fecal Microbiota Transplantation) is a medical procedure in which healthy gut bacteria from a donor are transferred to a patient to restore a balanced intestinal microbiome.
Things worth knowing about "FMT"
FMT (Fecal Microbiota Transplantation) is a medical procedure in which healthy gut bacteria from a donor are transferred to a patient to restore a balanced intestinal microbiome.
What is Fecal Microbiota Transplantation (FMT)?
Fecal Microbiota Transplantation (FMT), also referred to as stool transplantation, is a medical procedure in which processed stool from a healthy, screened donor is introduced into the gastrointestinal tract of a patient. The primary goal is to restore a healthy gut microbiome – the complex community of microorganisms living in the intestine – and to displace harmful, disease-causing bacteria.
Background and Mechanism of Action
The human gut is home to trillions of bacteria, viruses, fungi, and other microorganisms that together form the microbiome. This ecosystem plays a critical role in digestion, immune function, and overall health. When this balance is significantly disrupted – a condition known as dysbiosis – pathogenic bacteria can overgrow and cause illness. This disruption is commonly triggered by prolonged antibiotic use, infections, or other environmental factors.
During FMT, carefully prepared donor stool is introduced into the gut of the recipient. The transferred microorganisms colonize the intestine, outcompete harmful bacteria, and re-establish a diverse and healthy microbial environment.
Indications and Uses
Approved and Established Indications
- Recurrent Clostridioides difficile infection (CDI): This is the most well-supported and widely approved indication for FMT. In patients with recurrent CDI that does not respond to antibiotics, FMT achieves cure rates of over 80–90 %.
Investigational and Experimental Indications
- Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease)
- Irritable bowel syndrome (IBS)
- Metabolic syndrome and obesity
- Neurological conditions (e.g., autism spectrum disorder, multiple sclerosis – currently experimental)
- Multidrug-resistant bacterial infections
Procedure and Administration
Donor Screening
Prior to FMT, donors undergo extensive screening for infectious diseases, parasites, and antibiotic-resistant organisms. Only donors who pass all screening criteria and demonstrate a healthy microbiome profile are approved for donation.
Preparation and Routes of Administration
Processed donor stool can be delivered through several routes:
- Colonoscopy – the most common and effective method, allowing deep delivery into the colon
- Enema – simpler but reaches less of the colon
- Nasojejunal tube or nasogastric tube – delivery via the upper gastrointestinal tract
- Capsules (freeze-dried stool preparations) – a modern, patient-friendly oral option
Efficacy and Safety
FMT is considered safe and highly effective for recurrent Clostridioides difficile infections. The most common side effects are transient and include bloating, abdominal cramps, and mild diarrhea following the procedure. Serious adverse events are rare but can occur in immunocompromised patients. A recognized safety concern is the potential transmission of multidrug-resistant organisms (e.g., ESBL-producing bacteria), which is mitigated through rigorous donor screening protocols.
Regulatory Status
In the United States, the FDA has approved two FMT-based products – Rebyota and Vowst – specifically for the prevention of recurrent CDI. In Europe and Germany, FMT is regulated as a medicinal product and is primarily administered within clinical trials or as an individual compassionate-use treatment. Regulatory frameworks continue to evolve as evidence for broader applications grows.
References
- Surawicz CM et al. – Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. American Journal of Gastroenterology, 2013; 108(4):478–498.
- Kassam Z et al. – Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2013; 108(4):500–508.
- U.S. Food and Drug Administration (FDA) – Approval of Rebyota and Vowst for Recurrent Clostridioides difficile Infection (2023). Available at: www.fda.gov.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.